## Charlene D Fell

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10423349/publications.pdf

Version: 2024-02-01

687363 580821 25 28 917 13 h-index citations g-index papers 29 29 29 951 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Travel Distance to Subspecialty Clinic and Outcomes in Patients with Fibrotic Interstitial Lung Disease. Annals of the American Thoracic Society, 2022, 19, 20-27.	3.2	16
2	Association of BMI and Change in Weight With Mortality in Patients With Fibrotic Interstitial Lung Disease. Chest, 2022, 161, 1320-1329.	0.8	25
3	Effect of continued antifibrotic therapy after forced vital capacity decline in patients with idiopathic pulmonary fibrosis; a real world multicenter cohort study. Respiratory Medicine, 2022, 191, 106722.	2.9	3
4	Prevalence and characteristics of progressive fibrosing interstitial lung disease in a prospective registry. European Respiratory Journal, 2022, 60, 2102571.	6.7	57
5	Prescribing Patterns and Tolerability of Mycophenolate and Azathioprine in Patients with Nonidiopathic Pulmonary Fibrosis Fibrotic Interstitial Lung Disease. Annals of the American Thoracic Society, 2022, 19, 863-867.	3.2	2
6	Inhalational exposures in patients with fibrotic interstitial lung disease: Presentation, pulmonary function and survival in the <scp>Canadian Registry</scp> for <scp>Pulmonary Fibrosis</scp> . Respirology, 2022, 27, 635-644.	2.3	12
7	Clinical characterization of patients with interstitial lung disease: Report from a single Canadian Center. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2021, 5, 310-315.	0.5	0
8	Treatment Initiation in Patients with Interstitial Lung Disease in Canada. Annals of the American Thoracic Society, 2021, 18, 1661-1668.	3.2	4
9	Validation and minimum important difference of the UCSD Shortness of Breath Questionnaire in fibrotic interstitial lung disease. Respiratory Research, 2021, 22, 202.	<b>3.</b> 6	5
10	Real-world patterns of pirfenidone use and safety in patients with idiopathic pulmonary fibrosis in Canada: Data from INSPIRATION PLUS. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2020, 4, 25-30.	0.5	0
11	Long-term monitoring of patients with fibrotic interstitial lung disease: A Canadian Thoracic Society Position Statement. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2020, 4, 147-155.	0.5	3
12	A cluster-based analysis evaluating the impact of comorbidities in fibrotic interstitial lung disease. Respiratory Research, 2020, 21, 322.	3.6	18
13	Costs of Workplace Productivity Loss in Patients with Connective Tissue Disease–associated Interstitial Lung Disease. Annals of the American Thoracic Society, 2020, 17, 1077-1084.	3.2	5
14	Costs of Workplace Productivity Loss in Patients With Fibrotic Interstitial Lung Disease. Chest, 2019, 156, 887-895.	0.8	14
15	Autoantibody status is not associated with change in lung function or survival in patients with idiopathic pulmonary fibrosis. Respiratory Medicine, 2019, 153, 85-90.	2.9	7
16	Comprehensive management of fibrotic interstitial lung diseases: A Canadian Thoracic Society position statement. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2018, 2, 234-243.	0.5	8
17	Transbronchial lung cryobiopsy for ILD: Ready or not, here it comes?. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2018, 2, 257-258.	0.5	0
18	Clinical and economic burden of idiopathic pulmonary fibrosis in Quebec, Canada. ClinicoEconomics and Outcomes Research, 2018, Volume 10, 127-137.	1.9	16

#	Article	IF	CITATIONS
19	Use of Mycophenolate Mofetil or Azathioprine for the Management of Chronic Hypersensitivity Pneumonitis. Chest, 2017, 151, 619-625.	0.8	177
20	Evaluation of patients with fibrotic interstitial lung disease: A Canadian Thoracic Society position statement. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2017, 1, 133-141.	0.5	15
21	Trends in diagnosis and management of idiopathic pulmonary fibrosis in Canada. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2017, 1, 71-76.	0.5	5
22	The Canadian Registry for Pulmonary Fibrosis: Design and Rationale of a National Pulmonary Fibrosis Registry. Canadian Respiratory Journal, 2016, 2016, 1-7.	1.6	45
23	High Oxygen Delivery to Preserve Exercise Capacity in Patients with Idiopathic Pulmonary Fibrosis Treated with Nintedanib. Methodology of the HOPE-IPF Study. Annals of the American Thoracic Society, 2016, 13, 1640-1647.	3.2	37
24	Pulmonary Manifestations of Systemic Lupus Erythematosus. Seminars in Respiratory and Critical Care Medicine, 2014, 35, 249-254.	2.1	70
25	Idiopathic Pulmonary Fibrosis: Phenotypes and Comorbidities. Clinics in Chest Medicine, 2012, 33, 51-57.	2.1	53
26	Clinical Predictors of a Diagnosis of Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2010, 181, 832-837.	5.6	220
27	The Prognostic Value of Cardiopulmonary Exercise Testing in Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2009, 179, 402-407.	5.6	98
28	PREDICTING IPF VS NSIP WITHOUT A SURGICAL LUNG BIOPSY. Chest, 2007, 132, 428C.	0.8	1